Table 2 Data indicating the incidence of events and morbidity in the matched cohorts
From: Aspirin reduces the risk of type 2 diabetes associated with COVID-19
Variable | No aspirin N= 4,139 | Aspirin N = 4139 | Difference | 95% CI |
|---|---|---|---|---|
Diabetes | 664 (16%) | 330 (8.0%) | 8.1% | 6.7%, 9.5% |
CKD | 750 (18%) | 1022 (25%) | −6.6% | −8.4%, −4.8% |
Dyslipidemia | 3,229 (78%) | 3243 (78%) | −0.34% | −2.1%, 1.5% |
CHD | 7 (0.2%) | 30 (0.7%) | −0.56% | −0.87%, −0.24% |
Myocardial infarction | 3 (<0.1%) | 36 (0.9%) | −0.80% | −1.1%, −0.48% |
Heart failure | 43 (1.0%) | 114 (2.8%) | −1.7% | −2.3%, −1.1% |
Ictus | 11 (0.3%) | 61 (1.5%) | −1.2% | −1.6%, −0.78% |
Cerebral hemorrhage | 3 (<0.1%) | 9 (0.2%) | −0.14% | −0.33%, 0.04% |
Gastroenteric hemorrhage | 88 (2.1%) | 172 (4.2%) | −2.0% | −2.8%, −1.3% |
Hematuria | 102 (2.5%) | 139 (3.4%) | −0.89% | −1.6%, −0.15% |
